The U.S. Centers for Disease Control and Prevention formally lifted its pause on the Johnson & Johnson vaccine after a panel on Friday recommended resuming its use , despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal. All were women, and most younger than 50. The panel said Friday that the vaccine’s benefits outweigh the serious but small risk. In Missouri, providers with the J&J vaccine in stock can immediately begin administering it and shipments from the federal government will resume this week.